Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr275.00 SEK
Change Today -4.50 / -1.61%
Volume 3.5K
BIOGB On Other Exchanges
Symbol
Exchange
OTC US
Berlin
Stockholm
OTC US
As of 5:24 AM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

biogaia ab-b shs (BIOGB) Snapshot

Open
kr280.00
Previous Close
kr279.50
Day High
kr280.00
Day Low
kr270.50
52 Week High
05/22/15 - kr292.00
52 Week Low
10/13/14 - kr150.10
Market Cap
4.7B
Average Volume 10 Days
15.5K
EPS TTM
kr5.41
Shares Outstanding
16.6M
EX-Date
05/8/15
P/E TM
50.8x
Dividend
kr3.46
Dividend Yield
1.82%
Current Stock Chart for BIOGAIA AB-B SHS (BIOGB)

Related News

No related news articles were found.

biogaia ab-b shs (BIOGB) Related Businessweek News

No Related Businessweek News Found

biogaia ab-b shs (BIOGB) Details

BioGaia AB develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through Paediatrics, Adult Health, and New Business segments. The company provides BioGaia ProTectis digestive health probiotic drops, as well as BioGaia ProTectis D3 drops with vitamin D3 containing lactobacillus reuteri protectis for children; and BioGaia ProTectis ORS, a probiotic oral rehydration solution with zinc. It also offers BioGaia ProTectis chewable tablet, a dietary supplement containing lactobacillus reuteri protectis, as well as BioGaia ProDentis oral lozenges, a dietary supplement containing lactobacillus reuteri prodentis for adults and children; BioGaia Gastrus, a probiotic supplement that could enhance treatment of Helicobacter pylori infection; and BioGaia ProTectis straw that provides lactobacillus reuteri protectis to various beverages. In addition, the company offers ProDentis oral health tablet for the treatment of periodontal disease and gingivitis; and component products, which are bacterial cultures of lactobacillus reuteri protectis that are used as ingredients in yoghurt and other dairy products. Further, it provides animal health products. The company sells its products through pharmacies and related outlets. BioGaia AB was founded in 1990 and is headquartered in Stockholm, Sweden.

98 Employees
Last Reported Date: 05/7/15
Founded in 1990

biogaia ab-b shs (BIOGB) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: kr2.3M
Compensation as of Fiscal Year 2014.

biogaia ab-b shs (BIOGB) Key Developments

Biogaia's Oral Health Probiotic Reduces Candida in the Elderly

BioGaia announced that its oral health probiotic reduces Candida in the elderly. A double-blind, randomised, placebo-controlled study in 215 elderly nursing home residents showed that Lactobacillus reuteri Prodentis reduced the prevalence of oral Candida by more than 50% compared to placebo. After 12 weeks of intervention with two lozenges per day of Lactobacillus reuteri Prodentis there was a statistically significant reduction of 53% in the proportion of patients that had high Candida counts in both saliva and plaque in the probiotic group whereas there was no difference in the placebo group.

BioGaia AB Approves Election of Board Members

BioGaia AB approved the election of Anthon Jahreskog and Ewa Björling as board members in the annual general meeting held on May 7, 2015. Anthon Jahreskog, born in 1980, Chief Operating Officer, Fund Linked Products, Credit Suisse Investment Bank, London. He has several years of experience from the international financial market and expertise in strategic business planning, cost efficiency and analysis. Anthon Jahreskog is independent of the company and its management and does not own any shares in BioGaia. Anthon Jahreskog does not serve any other boards. Ewa Björling, born in 1961, is a trained dentist and a Doctor of Medicine and senior lecturer in virology with many years of experience from Karolinska institutet. Ewa Björling has also been a member of the Riksdag and the Minister for Trade in the Swedish government from 2007 to 2014. Ewa Björling is independent of the company and its management and does not own any shares in BioGaia.

BioGaia AB Proposes Ordinary Dividend and an Extraordinary Dividend

The Board of Directors of BioGaia AB proposed that the forthcoming AGM be asked to approve an ordinary dividend of SEK 3.46 per share and an extraordinary dividend of SEK 1.54 per share, which makes a total dividend of SEK 5.00 per share. This will amount to a shareholders' dividend of SEK 86.4 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOGB:SS kr275.00 SEK -4.50

BIOGB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BLIS Technologies Ltd $0.02 NZD -0.002
Danone SA €62.17 EUR +0.48
Oragenics Inc $2.62 USD +0.40
Probi AB kr160.00 SEK +13.75
Yakult Honsha Co Ltd ¥8,370 JPY +140.00
View Industry Companies
 

Industry Analysis

BIOGB

Industry Average

Valuation BIOGB Industry Range
Price/Earnings 51.7x
Price/Sales 11.2x
Price/Book 12.4x
Price/Cash Flow 49.7x
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGAIA AB-B SHS, please visit www.biogaia.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.